Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Bioenerg Biomembr. Author manuscript; available in PMC 2010 August 2.
Published in final edited form as:
PMCID: PMC2913874

The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease


Huntington disease (HD) is an inherited neuro-degenerative disease caused by an abnormal expansion of the CAG repeat region in the huntingtin (Htt) gene. Although the pathogenic mechanisms by which mutant Htt (mHtt) causes HD have not been fully elucidated, it is becoming increasingly apparent that mHtt can impair mitochondrial function directly, as well as indirectly by dysregulation of transcriptional processes. mHtt causes increased sensitivity to Ca2+-induced decreases in state 3 respiration and mitochondrial permeability transition pore (mPTP) opening concurrent with a reduction in mitochondrial Ca2+ uptake capacity. Treatment of striatal cells expressing mHtt with thapsigargin results in a decrease in mitochondrial Ca2+ uptake and membrane potential and an increase in reactive oxygen species (ROS) production. Transcriptional processes regulated by peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α (PGC-1α), which are critical for mitochondrial biogenesis, have been shown to be impaired in HD. In addition, the PPARγ signaling pathway is impaired by mHtt and the activation of this pathway ameliorates many of the mitochondrial deficits, suggesting that PPARγ agonists may represent an important treatment strategy for HD.

Keywords: Mitochondria, Huntingtin, PGC-1α/PPARγ, Ca 2+, Respiration


Huntington disease (HD) is an autosomal dominant inherited disease caused by an abnormal expansion of CAG repeats in exon 1 of the huntingtin (Htt) gene located on chromosome 4p16.3, resulting in a pathological elongation of polyglut-amine in the Htt protein. HD is one of nine polyglutamine diseases with the only common feature being the expansion of a polyglutamine domain in the disease-specific protein (Orr and Zoghbi 2007; Shao and Diamond 2007). HD patients exhibit neuronal degeneration predominantly in striatum and at the later stage of disease in cerebral cortex. GABAergic medium size spiny neurons (MSNs) undergo neurodegeneration, whereas interneurons survive in striatum of HD patients (Ferrante et al. 1991). Clinical manifestations of HD consist of progressive behavioral and motor abnormalities, psychiatric disturbance, and cognitive disorder. Although the mutation in Htt gene was discovered more than 17 years ago (The Huntington’s Disease Collaborative Research Group 1993), the molecular role of Htt in the cell and the pathological mechanisms that result from the presence of mutant Htt (mHtt) are still under investigation. When intraneuronal aggregates containing mHtt were first discovered in the brain of HD patients and HD mouse models it was suggested that they had a causative role (Davies et al. 1997; DiFiglia et al. 1997; Scherzinger et al. 1997). However, more recent studies indicate that the aggregates in HD may not be a causative factor per se, and in fact may actually play a protective role, findings that have led investigators to concentrate on other pathogenic aspects in HD (Slow et al. 2006). A growing number of studies provide evidence that mHtt results in mitochondrial impairment such as defects in the electron transport chain (ETC) activity, reduced Ca2+ uptake capacity, and increased sensitivity of mitochondria to Ca2+-induced permeability transition pore (mPTP) opening. Furthermore, data now indicate that the translocation of mHtt into nucleus and transcriptional dysregulation likely play an important role in the pathogenic process (Saudou et al. 1998), and more specifically these events have a significant impact on mitochondria (Greenamyre 2007; Ross and Thompson 2006).

Indications of mitochondrial dysfunction in HD patients

Energetic impairment in HD patients has been observed in many studies by a variety of methods. For example, positron emission tomography (PET) scans that utilize 18F-2-deoxyglucose (18F-2-DOG) showed a significant reduction in glucose uptake in cortex and striatum of HD patients even prior to striatal neuronal loss and pathological symptoms (Gil and Rego 2008). Paradoxical increases in lactate have been observed in the cortex of symptomatic HD patients and in the striatum of presymptomatic HD patients using 1H-magnetic resonance spectroscopy (MRS) (Jenkins et al. 1998). Furthermore, most HD patients suffer weight loss and muscle wasting in spite of constant food intake (Djousse et al. 2002; Kirkwood et al. 2001; Sanberg et al. 1981). These studies clearly indicate the involvement of bioenergetic deficits in HD.

Mitochondria are essential organelle that are involved in many vital processes such as energy production through oxidative phosphorylation (Oxphos) via the tricarboxylic acid (TCA) cycle, fatty acid oxidation and the electron transport chain (ETC), thermogenesis, cell death mechanisms, defense against reactive oxygen species (ROS), and Ca2+ buffering. Early ultrastructural studies using cerebral cortical tissue obtained from HD patients revealed abnormal neuronal mitochondrial morphology (Goebel et al. 1978; Tellez-Nagel et al. 1974). In addition, functional defects have been observed. For example, deficits in succinate dehydrogenase activity, a component of complex II of ETC as well as the TCA cycle, were observed in postmortem HD brains in 1974 (Stahl and Swanson 1974). Reduced expression of complex II subunits has been observed in striatum of HD patients (Benchoua et al. 2006). The activities of complex III in the caudate and putamen and complex IV in the putamen are also significantly decreased in HD cases (Gil and Rego 2008). The activity of aconitase, an essential enzyme in the TCA cycle, has been reported to be significantly decreased in the striatum and cerebral cortex (Tabrizi et al. 2000), and loss of the pyruvate dehydrogenase complex was observed in symptomatic patients with caudate/putamen atrophy (Butterworth et al. 1985; Sorbi et al. 1983). Concurrent with these changes in mitochondrial morphology and function, there is a significant decrease in mitochondrial DNA in the cerebral cortex of HD patients (Horton et al. 1995).

Although studies have focused primarily on the brain, mitochondrial abnormalities have been observed outside of the brain in HD cases. A deficit in complex I was first reported in muscle of HD patients (Arenas et al. 1998), although another recent study showed no significant differences in the activities of complexes I and IV (Turner et al. 2007). However, in this latter study, significant correlations between the activity of complexes II–III and disease duration/progress were noted, along with evidence of inclusion formation in HD muscle (Turner et al. 2007). 31P-MRS showed significantly reduced ATP production in muscle of presymptomatic and symptomatic HD patients (Lodi et al. 2000). Other groups found out abnormal morphologies as well as decreased membrane potential in mitochondria from peripheral tissues including lymphoblasts and muscle of HD patients (Panov et al. 2002; Squitieri et al. 2006, 2010). As in the brain, mitochondrial DNA in leukocytes from HD patients was depleted (Liu et al. 2008).

Mitochondrial impairment in cell and mouse models of HD

Numerous studies in cell and mouse models of HD have revealed mitochondrial impairment. The hypothesis that mitochondrial dysfunction contributes to the pathogenesis of HD was first tested pharmacologically by using 3-nitropropionic acid (3-NP), an irreversible-, and malonate, a reversible inhibitor of succinate dehydrogenase. Administration of these inhibitors to animals results in pathological characteristics of HD such as marked increases in striatal lactate concentration and striatal lesions (Beal et al. 1993; Brouillet et al. 1993; Frim et al. 1993). In addition, mitochondria isolated from the striatum of adult rats are more sensitive to Ca2+-induced mPTP opening than mitochondria from the cerebral cortex of adult rats (Brustovetsky et al. 2003). These and other findings suggest that mitochondria in striatal neurons, especially MSNs, are selectively vulnerable to metabolic stress which may contribute to the selective loss of these neurons in HD.

The first mouse model of HD, the R6/2 line, was produced by expressing exon 1 of the Htt gene with an expanded CAG repeat (Mangiarini et al. 1996). These mice have been used extensively in HD studies and exhibit mitochondrial abnormalities. R6/2 transgenic mice exhibit increases in mitochondrial DNA damage (Acevedo-Torres et al. 2009), and a significant reduction in aconitase and complex IV activities in striatum and complex IV activity in cerebral cortex (Tabrizi et al. 2000). A decreased stability of muscle mitochondria against Ca2+-induced mPTP opening and an increased sensitivity of complex I-dependent respiration against Ca2+-induced inhibition have been found in R6/2 mice, leading to energetic deficits and muscle atrophy (Gizatullina et al. 2006).

Clonal striatal precursor cells established from striatal primordia of E16 embryos of wild-type (STHdhQ7/Q7) and mHtt (STHdhQ111/Q111) knock-in mice (Trettel et al. 2000) have been used in studies of mitochondrial function. Mitochondria from STHdhQ111/Q111 striatal cells, show significantly reduced respiration and ATP production as compared with mitochondria from STHdhQ7/Q7 striatal cells, when either glutamate/malate or succinate was used as the substrate, despite equivalent levels of ETC complex activities in the two cell lines. However, when the artificial electron donor TMPD/ascorbate for complex IV was used as the substrate, there was no difference in mitochondrial respiration between two cell lines (Milakovic and Johnson 2005). Taken together, these mouse and cell models exhibit mitochondrial impairment and metabolic deficits similar to the pathological characteristics that have been observed in HD (Damiano et al. 2010; Quintanilla and Johnson 2009). Interestingly, yeast expressing mHtt showed a significant reduction in mitochondrial Oxphos due to an alteration in complex II and III (Solans et al. 2006).

Ca2+ handling defects and mitochondrial membrane potential (ΔΨm) depolarization

Panov et al. (2002) showed that mitochondria isolated from lymphoblasts of HD patients have decreased Ca2+-buffering capacity and undergo mitochondrial membrane depolarization at lower Ca2+ concentrations. They also found similar abnormalities in mitochondria from YAC72 mice expressing full-length mHtt with a polyglutamine stretch of 72, but not from YAC18 mice expressing full-length Htt with a polyglutamine stretch of 18. Mitochondrial localization of mHtt as detected by immunocytochemistry and electron microscopy, suggested a direct interaction between mHtt and mitochondria (Panov et al. 2002). Choo et al. (2004) showed that huntingtin was present in the mitochondrial fraction purified from human neuroblastoma cells and clonal striatal cells and associated with the outer mitochondrial membrane. A recombinant truncated mHtt directly added to isolated mouse liver mitochondria significantly decreased the Ca2+-threshold for mPTP opening, an effect that was abolished by cyclosporin A (CsA), an mPTP inhibitor. Mitochondria isolated from a knock-in (150/150) HD mouse showed a similar increased susceptibility to Ca2+-induced mPTP opening (Choo et al. 2004). Mitochondria from STHdhQ111/Q111 cells were more sensitive to Ca2+-induced decreases in state 3 respiration and mitochondrial membrane potential than mitochondria from STHdhQ7/Q7 cells (Milakovic et al. 2006). Importantly, mitochondria from STHdhQ111/Q111 cells showed a significant reduction in Ca2+ uptake capacity compared with mitochondria from STHdhQ7/Q7 cells (Lim et al. 2008; Milakovic et al. 2006). ADP treatment attenuated the mitochondrial membrane potential defect and CsA treatment prevented the decreases in Ca2+ uptake capacity (Milakovic et al. 2006). Striatal neurons from Hdh150 knock-in mice exhibit increased susceptibility to Ca2+-deregulation by NMDA receptor activation than striatal neurons from wild type littermates, when pyruvate instead of glucose is used in media to emphasize Oxphos dependent bioenergetics (Oliveira et al. 2007). These findings clearly indicate that mHtt induces Ca2+ handling defects, respiratory deficits, and increased sensitivity to Ca2+-inducded mPTP opening in mitochondria.

In addition to increasing the sensitivity of mitochondria to Ca2+-induced mPTP opening, mHtt could contribute to the vulnerability of MSNs by causing increased Ca2+ loading. mHtt directly interacts with C-terminal region of the type 1 inositol 1,4,5-trisphosphate (InsP3) receptor (InsP3R1), resulting in increased sensitivity of InsP3R1 to activation by InsP3 (Tang et al. 2003). The implication of InsP3R1 activation for mHtt-induced toxicity was corroborated in MSN cultures from a HD mouse model using a pharmacological approach (Tang et al. 2005) and in a Drosophila HD model using genetic experiments (Kaltenbach et al. 2007). Moreover, mHtt enhances the activity of N-methyl D-aspartate receptors (NMDARs) harboring the NR2B subunit, resulting from increased NMDAR trafficking to the plasma membrane (Fan et al. 2007; Sun et al. 2001; Zeron et al. 2002). Importantly, MSNs express high levels of the NR2B subunit, implying a greater sensitivity to excitotoxicity caused by NMDAR activation (Heng et al. 2009; Rigby et al. 1996). In addition, inhibition of mPTP opening by treatment with CsA and bongkrekic acid significantly diminished NMDA-induced Ca2+ influx and mitochondrial membrane potential loss in MSNs of YAC128 mouse (Fernandes et al. 2007). Similarly, Htt is likely to have an effect on the function of the voltage-gated Ca2+ channels (VGCCs), because Htt associates with the synaptic protein interaction (synprint) region of N-type VGCC (Swayne et al. 2005) and the α2/δ auxiliary subunit of VGCC (Kaltenbach et al. 2007), and MSNs from R6/2 mice at 3–6 weeks of age show increases in voltage-gated Ca2+ conductances (Cepeda et al. 2007). Photoreceptor neurodegeneration in an HD fly model expressing a full length of mHtt with a polyglutamine stretch of 128 was rescued by removing one copy of Dmca1D (a L-type VGCC pore subunit of Drosophila) (Romero et al. 2008).

Involvement of transcriptional dysregulation in mitochondrial impairment in HD

Initial studies showed that mHtt interferes with cAMP-responsive element (CRE) binding protein (CREB) mediated transcriptional processes through direct interaction with CBP (CREB-binding protein) (Steffan et al. 2000) and with TATA box-binding protein (TBP)-associated factor TAF4/ TAFII130 (Dunah et al. 2002; Shimohata et al. 2000), leading to an increase in mHtt-induced cytotoxicity (Steffan et al. 2001).

The peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α (PGC-1α) is an orchestrator of mitochondrial function via integration of signals that regulate mitochondrial biogenesis and respiration, detoxification of ROS, energy metabolism, and thermogenesis (Houten and Auwerx 2004). PGC-1α interacts with a number of transcription factors including PPARγ of the PPAR family, which regulates adipogenesis and lipid metabolism, and the nuclear respiratory factor-1/2 (NRF-1/2) which play a pivotal role in mitochondrial respiration. The expression of PGC-1α is repressed in both in vitro and in vivo models of HD, at least partially due to the fact that mHtt directly interferes with the CREB/TAF4 signaling pathway which is a predominant regulator of PGC-1α expression (Cui et al. 2006). The reduced level of cAMP in HD mice and HD patients likely contributes to the significant reduction in CREB activation (Gines et al. 2003). Since CREB is one of major transcription factors for PGC-1α, cAMP reduction may affect the expression of PGC-1α. A role for PGC-1α in the pathogenesis of HD is further supported by the studies showing that primary striatal neurons are significantly protected from mHtt-induced toxicity by exogenous expression of PGC-1α and lentiviral delivery of PGC-1α into the striatum of HD mice attenuates the atrophy (Cui et al. 2006).

PPARγ plays a central role in genes involved in fatty acid oxidation and mitochondrial function. PPARγ hetero-dimerizes with retinoid X receptor (RXR) in the presence or absence of ligand (Glass and Ogawa 2006). Upon ligand binding, PPARγ transactivates the target genes with the support of coactivators such as PGC-1α. Clinically important exogenous ligands of PPARα are thiazolidinediones (TZDs) (rosiglitazone, pioglitazone, troglitazone). TZDs are used in the treatment of type II diabetes. Recent studies demonstrate that TZDs show protective effects in models of Alzheimer’s disease (Heneka et al. 2005; Landreth 2006), Parkinson’s disease (Breidert et al. 2002), amyotrophic lateral sclerosis (Kiaei et al. 2005), stroke (Luo et al. 2006), and multiple sclerosis (Niino et al. 2001). More importantly, we found out that STHdhQ111/Q111 cells exhibit significant decreases in PPARγ activity, that thapsigargin induced a decrease in mitochondrial membrane potential and an increase in ROS production only in STHdhQ111/Q111 cells, and that PPARγ activation by rosiglitazone treatment protected STHdhQ111/Q111 cells from thapsigargin-induced mitochondrial membrane potential loss and ROS production (Quintanilla et al. 2008). These studies suggest that PGC-1α/PPARγ could be contributing factors in mitochondrial deficits in HD and the activation of PGC-1α/PPARγ could result in the protection of striatal neurons from mHtt toxicity.

Concluding remarks

The pathogenic mechanisms of HD have been shown to involve mitochondrial deficits such as increased sensitivities to Ca2+-induced decreases in state 3 respiration and to Ca2+-induced mPTP opening, a decrease in ATP production and in Ca2+ uptake capacity, and an increase in ROS production. mHtt could contribute to the vulnerability of MSNs by causing increased Ca2+ loading via increased activities of InsP3R1, NMDARs, and VGCCs. mHtt can impair mitochondrial function directly, as well as indirectly by dysregulation of transcriptional processes. PGC-1α/ PPARγ pathway has been shown to be disrupted in HD patients and HD models, at least in part due to the interference with CREB/TAF4 signaling pathway. The activation of PGC-1α/PPARγ leads to the protective effects in HD models (Fig. 1). These findings may lead to a deeper understanding of the pathogenic mechanism of HD and suggest a potential approach of therapeutics for HD.

Fig. 1
Schematic Diagram of Mitochondrial Impairment Caused by Mutant Huntingtin. Mutant huntingtin (mHtt) enhances the activities of: (1) NMDA receptors (NMDARs), especially those containing NR2B subunit via increased receptor trafficking, (2) voltage-gated ...


Work from the authors’ laboratory was supported by an NIH grant (NS041744).


  • Acevedo-Torres K, Berrios L, Rosario N, Dufault V, Skatchkov S, Eaton MJ, Torres-Ramos CA, Ayala-Torres S. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington’s disease. DNA Repair (Amst) 2009;8(1):126–136. [PMC free article] [PubMed]
  • Arenas J, Campos Y, Ribacoba R, Martin MA, Rubio JC, Ablanedo P, Cabello A. Complex I defect in muscle from patients with Huntington’s disease. Ann Neurol. 1998;43(3):397–400. [PubMed]
  • Beal MF, Brouillet E, Jenkins B, Henshaw R, Rosen B, Hyman BT. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem. 1993;61(3):1147–1150. [PubMed]
  • Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N, Saudou F, Elalouf JM, Hirsch E, Hantraye P, et al. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell. 2006;17(4):1652–1663. [PMC free article] [PubMed]
  • Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson’s disease. J Neurochem. 2002;82(3):615–624. [PubMed]
  • Brouillet E, Jenkins BG, Hyman BT, Ferrante RJ, Kowall NW, Srivastava R, Roy DS, Rosen BR, Beal MF. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem. 1993;60(1):356–359. [PubMed]
  • Brustovetsky N, Brustovetsky T, Purl KJ, Capano M, Crompton M, Dubinsky JM. Increased susceptibility of striatal mitochondria to calcium-induced permeability transition. J Neurosci. 2003;23(12):4858–4867. [PubMed]
  • Butterworth J, Yates CM, Reynolds GP. Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in postmortem brain from Huntington’s disease and agonal cases. J Neurol Sci. 1985;67(2):161–171. [PubMed]
  • Cepeda C, Wu N, Andre VM, Cummings DM, Levine MS. The corticostriatal pathway in Huntington’s disease. Prog Neurobiol. 2007;81(5–6):253–271. [PMC free article] [PubMed]
  • Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cyto-chrome c release. Hum Mol Genet. 2004;13(14):1407–1420. [PubMed]
  • Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006;127(1):59–69. [PubMed]
  • Damiano M, Galvan L, Deglon N, Brouillet E. Mitochondria in Huntington’s disease. Biochim Biophys Acta. 2010;1802(1):52–61. [PubMed]
  • Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90(3):537–548. [PubMed]
  • DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. Aggregation of huntingtin in neuronal intra-nuclear inclusions and dystrophic neurites in brain. Science. 1997;277 (5334):1990–1993. [PubMed]
  • Djousse L, Knowlton B, Cupples LA, Marder K, Shoulson I, Myers RH. Weight loss in early stage of Huntington’s disease. Neurology. 2002;59(9):1325–1330. [PubMed]
  • Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N, Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington’s disease. Science. 2002;296(5576):2238–2243. [PubMed]
  • Fan MM, Fernandes HB, Zhang LY, Hayden MR, Raymond LA. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington’s disease. J Neurosci. 2007;27(14):3768–3779. [PubMed]
  • Fernandes HB, Baimbridge KG, Church J, Hayden MR, Raymond LA. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington’s disease. J Neurosci. 2007;27(50):13614–13623. [PubMed]
  • Ferrante RJ, Kowall NW, Richardson EP., Jr Proliferative and degenerative changes in striatal spiny neurons in Huntington’s disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J Neurosci. 1991;11(12):3877–3887. [PubMed]
  • Frim DM, Simpson J, Uhler TA, Short MP, Bossi SR, Breakefield XO, Isacson O. Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF. J Neurosci Res. 1993;35(4):452–458. [PubMed]
  • Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington’s disease. Eur J Neurosci. 2008;27(11):2803–2820. [PubMed]
  • Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, Wheeler VC, Persichetti F, MacDonald ME. Specific progressive cAMP reduction implicates energy deficit in pre-symptomatic Huntington’s disease knock-in mice. Hum Mol Genet. 2003;12(5):497–508. [PubMed]
  • Gizatullina ZZ, Lindenberg KS, Harjes P, Chen Y, Kosinski CM, Landwehrmeyer BG, Ludolph AC, Striggow F, Zierz S, Gellerich FN. Low stability of Huntington muscle mitochondria against Ca2+ in R6/2 mice. Ann Neurol. 2006;59(2):407–411. [PubMed]
  • Glass CK, Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol. 2006;6(1):44–55. [PubMed]
  • Goebel HH, Heipertz R, Scholz W, Iqbal K, Tellez-Nagel I. Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology. 1978;28(1):23–31. [PubMed]
  • Greenamyre JT. Huntington’s disease—making connections. N Engl J Med. 2007;356(5):518–520. [PubMed]
  • Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O’Banion K, Klockgether T, Van Leuven F, Landreth GE. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain. 2005;128(Pt 6):1442–1453. [PubMed]
  • Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci. 2009;29(10):3200–3205. [PubMed]
  • Horton TM, Graham BH, Corral-Debrinski M, Shoffner JM, Kaufman AE, Beal MF, Wallace DC. Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington’s disease patients. Neurology. 1995;45(10):1879–1883. [PubMed]
  • Houten SM, Auwerx J. PGC-1alpha: turbocharging mitochondria. Cell. 2004;119(1):5–7. [PubMed]
  • Jenkins BG, Rosas HD, Chen YC, Makabe T, Myers R, MacDonald M, Rosen BR, Beal MF, Koroshetz WJ. 1H NMR spectroscopy studies of Huntington’s disease: correlations with CAG repeat numbers. Neurology. 1998;50(5):1357–1365. [PubMed]
  • Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, Strand A, Torcassi C, Savage J, Hurlburt A, et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 2007;3(5):e82. [PubMed]
  • Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2005;191(2):331–336. [PubMed]
  • Kirkwood SC, Su JL, Conneally P, Foroud T. Progression of symptoms in the early and middle stages of Huntington disease. Arch Neurol. 2001;58(2):273–278. [PubMed]
  • Landreth G. PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer’s disease. Exp Neurol. 2006;199 (2):245–248. [PubMed]
  • Lim D, Fedrizzi L, Tartari M, Zuccato C, Cattaneo E, Brini M, Carafoli E. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J Biol Chem. 2008;283(9):5780–5789. [PubMed]
  • Liu CS, Cheng WL, Kuo SJ, Li JY, Soong BW, Wei YH. Depletion of mitochondrial DNA in leukocytes of patients with poly-Q diseases. J Neurol Sci. 2008;264(1–2):18–21. [PubMed]
  • Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, Warner TT. Abnormal in vivo skeletal muscle energy metabolism in Huntington’s disease and dentatorubropallidoluysian atrophy. Ann Neurol. 2000;48(1):72–76. [PubMed]
  • Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH, Chen J. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem. 2006;97(2):435–448. [PubMed]
  • Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3):493–506. [PubMed]
  • Milakovic T, Johnson GV. Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem. 2005;280(35):30773–30782. [PubMed]
  • Milakovic T, Quintanilla RA, Johnson GV. Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J Biol Chem. 2006;281 (46):34785–34795. [PubMed]
  • Niino M, Iwabuchi K, Kikuchi S, Ato M, Morohashi T, Ogata A, Tashiro K, Onoe K. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J Neuroimmunol. 2001;116(1):40–48. [PubMed]
  • Oliveira JM, Jekabsons MB, Chen S, Lin A, Rego AC, Goncalves J, Ellerby LM, Nicholls DG. Mitochondrial dysfunction in Huntington’s disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. J Neurochem. 2007;101(1):241–249. [PubMed]
  • Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci. 2007;30:575–621. [PubMed]
  • Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT. Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci. 2002;5(8):731–736. [PubMed]
  • Quintanilla RA, Johnson GV. Role of mitochondrial dysfunction in the pathogenesis of Huntington’s disease. Brain Res Bull. 2009;80(4–5):242–247. [PMC free article] [PubMed]
  • Quintanilla RA, Jin YN, Fuenzalida K, Bronfman M, Johnson GV. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) in the pathogenesis of Huntington disease. J Biol Chem. 2008;283(37):25628–25637. [PMC free article] [PubMed]
  • Rigby M, Le Bourdelles B, Heavens RP, Kelly S, Smith D, Butler A, Hammans R, Hills R, Xuereb JH, Hill RG, et al. The messenger RNAs for the N-methyl-D-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain. Neuroscience. 1996;73(2):429–447. [PubMed]
  • Romero E, Cha GH, Verstreken P, Ly CV, Hughes RE, Bellen HJ, Botas J. Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron. 2008;57(1):27–40. [PMC free article] [PubMed]
  • Ross CA, Thompson LM. Transcription meets metabolism in neurodegeneration. Nat Med. 2006;12(11):1239–1241. [PubMed]
  • Sanberg PR, Fibiger HC, Mark RF. Body weight and dietary factors in Huntington’s disease patients compared with matched controls. Med J Aust. 1981;1(8):407–409. [PubMed]
  • Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998;95 (1):55–66. [PubMed]
  • Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, Bates GP, Davies SW, Lehrach H, Wanker EE. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 1997;90 (3):549–558. [PubMed]
  • Shao J, Diamond MI. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet. 2007;16(Spec No 2):R115–R123. [PubMed]
  • Shimohata T, Nakajima T, Yamada M, Uchida C, Onodera O, Naruse S, Kimura T, Koide R, Nozaki K, Sano Y, et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet. 2000;26(1):29–36. [PubMed]
  • Slow EJ, Graham RK, Hayden MR. To be or not to be toxic: aggregations in Huntington and Alzheimer disease. Trends Genet. 2006;22(8):408–411. [PubMed]
  • Solans A, Zambrano A, Rodriguez M, Barrientos A. Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum Mol Genet. 2006;15(20):3063–3081. [PubMed]
  • Sorbi S, Bird ED, Blass JP. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol. 1983;13(1):72–78. [PubMed]
  • Squitieri F, Cannella M, Sgarbi G, Maglione V, Falleni A, Lenzi P, Baracca A, Cislaghi G, Saft C, Ragona G, et al. Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mech Ageing Dev. 2006;127 (2):217–220. [PubMed]
  • Squitieri F, Falleni A, Cannella M, Orobello S, Fulceri F, Lenzi P, Fornai F. Abnormal morphology of peripheral cell tissues from patients with Huntington disease. J Neural Transm. 2010;117(1):77–83. [PubMed]
  • Stahl WL, Swanson PD. Biochemical abnormalities in Huntington’s chorea brains. Neurology. 1974;24(9):813–819. [PubMed]
  • Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP, Housman DE, Thompson LM. The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A. 2000;97(12):6763–6768. [PubMed]
  • Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu YZ, Greenwald M, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001;413(6857):739–743. [PubMed]
  • Sun Y, Savanenin A, Reddy PH, Liu YF. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem. 2001;276(27):24713–24718. [PubMed]
  • Swayne LA, Chen L, Hameed S, Barr W, Charlesworth E, Colicos MA, Zamponi GW, Braun JE. Crosstalk between huntingtin and syntaxin 1A regulates N-type calcium channels. Mol Cell Neurosci. 2005;30(3):339–351. [PubMed]
  • Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol. 2000;47(1):80–86. [PubMed]
  • Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1, 4, 5) triphosphate receptor type 1. Neuron. 2003;39(2):227–239. [PMC free article] [PubMed]
  • Tang TS, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, Llinas R, Kristal BS, Hayden MR, Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington’s disease. Proc Natl Acad Sci U S A. 2005;102(7):2602–2607. [PubMed]
  • Tellez-Nagel I, Johnson AB, Terry RD. Studies on brain biopsies of patients with Huntington’s chorea. J Neuropathol Exp Neurol. 1974;33(2):308–332. [PubMed]
  • The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72 (6):971–983. [PubMed]
  • Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, Cattaneo E, MacDonald ME. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet. 2000;9(19):2799–2809. [PubMed]
  • Turner C, Cooper JM, Schapira AH. Clinical correlates of mitochondrial function in Huntington’s disease muscle. Mov Disord. 2007;22(12):1715–1721. [PubMed]
  • Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease. Neuron. 2002;33(6):849–860. [PubMed]